| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc. | Director | Common Stock | 105,843 | $245,555 | $2.32 | 02 Jun 2025 | Direct |
| Kaleido Biosciences, Inc. | Chief Medical Officer | Restricted Stock Units | 125,000 | 14 Jan 2022 | Direct | ||
| Taysha Gene Therapies, Inc. | Director | Stock Option (right to buy) | 113,246 | 02 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | 02 Jun 2025 | 2 | $0 | 4 | Director | 04 Jun 2025, 16:15 |
| TSHA | Taysha Gene Therapies, Inc. | 29 May 2024 | 2 | $0 | 4 | Director | 31 May 2024, 16:18 |
| TSHA | Taysha Gene Therapies, Inc. | 01 Nov 2023 | 1 | $0 | 4 | Director | 03 Nov 2023, 16:41 |
| TSHA | Taysha Gene Therapies, Inc. | 01 Nov 2023 | 0 | $0 | 3 | Director | 03 Nov 2023, 16:40 |
| KLDO | Kaleido Biosciences, Inc. | 14 Jan 2022 | 2 | $0 | 4 | Chief Medical Officer | 18 Jan 2022, 16:15 |
| KLDO | Kaleido Biosciences, Inc. | 15 Dec 2021 | 2 | $0 | 4 | Chief Medical Officer | 16 Dec 2021, 16:18 |
| KLDO | Kaleido Biosciences, Inc. | 15 Dec 2021 | 0 | $0 | 3 | Chief Medical Officer | 16 Dec 2021, 16:16 |